| Alzheimer Disease |
1 |
1 |
| Aducanumab |
0 |
0.87 |
| Patient Safety |
0 |
0.43 |
| Food and Drug Administration (FDA) |
0 |
0.36 |
| Medicare |
0 |
0.26 |
| Social Determinants of Health |
0 |
0.24 |
| Europe |
0 |
0.2 |
| NHS |
0 |
0.17 |
| Adverse Effects |
0 |
0.15 |
| Health Care Services |
0 |
0.07 |
| Amyloid-Beta |
0 |
0.05 |
| Brain |
0 |
0.05 |
| Grant |
0 |
0.05 |
| Health Care Facilities, Manpower, and Services |
0 |
0.05 |
| Health Care Quality, Access, and Evaluation |
0 |
0.05 |
| Medicaid |
0 |
0.05 |
| Memory |
0 |
0.05 |
| UK Site Content |
0 |
0.05 |